Skip to main content
SpringerLink
Log in

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490–9.

    Article  CAS  PubMed  Google Scholar 

  2. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  PubMed  Google Scholar 

  3. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.

    Article  CAS  PubMed  Google Scholar 

  4. Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, et al. Prognostic value of 18F-FLT PET in patients with neuroendocrine neoplasms: a prospective head-to-head comparison with 18F-FDG PET and Ki-67 in 100 patients. J Nucl Med. 2016;57:1851–7.

    Article  PubMed  Google Scholar 

  5. Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786–90.

    Article  CAS  PubMed  Google Scholar 

  6. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82.

    Article  PubMed  Google Scholar 

  8. Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 2016;43:1585–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology. 2016;103:432–9.

    Article  CAS  PubMed  Google Scholar 

  10. Hofman MS, Michael M, Kashyap R, Hicks RJ. Modifying the poor prognosis associated with 18F-FDG-avid NET with peptide receptor chemo-radionuclide therapy (PRCRT). J Nucl Med. 2015;56:968–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Houston Methodist Research Institute, Houston, TX, USA

    Paolo Zanotti-Fregonara

  2. Service de Médecine Nucléaire - CHU de Bordeaux; UMR-CNRS 5287; LabEx TRAIL, Université de Bordeaux, Bordeaux, France

    Clément Morgat & Elif Hindié

  3. CNRS/IN2P3, Centre d’Etudes Nucléaires de Bordeaux Gradignan (CENBG), Université de Bordeaux, Bordeaux, France

    Christophe Champion

Authors
  1. Paolo Zanotti-Fregonara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clément Morgat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christophe Champion
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elif Hindié
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Zanotti-Fregonara.

Ethics declarations

Ethical approval

This article does not contain any studies with animals performed by any of the authors.

Conflict of interest

The authors declare they have no conflict of interest.

Additional information

Letter about the article by Sansovini et al. “Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499.”

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zanotti-Fregonara, P., Morgat, C., Champion, C. et al. Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. Eur J Nucl Med Mol Imaging 44, 1095–1096 (2017). https://doi.org/10.1007/s00259-017-3667-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3667-7

Keywords

Search

Navigation